Genetic variants and social benefit receipt in premenopausal women with breast cancer treated with docetaxel: a Danish population-based cohort study
We found no clinically meaningful impact of the selected SNPs on social benefit receipt among premenopausal breast cancer survivors treated with docetaxel.
Authors
- Bent Ejlertsen (ORCID: https://orcid.org/0000-0001-8761-714X)
- Timothy L. Lash (ORCID: https://orcid.org/0000-0002-5240-5195)
- Julie A. Schmidt (ORCID: https://orcid.org/0000-0002-7733-8750)
- Per Damkier (ORCID: https://orcid.org/0000-0003-0591-7187)
- Deirdre Cronin‐Fenton (ORCID: https://orcid.org/0000-0001-9738-2284)
- Stephen Jacques Hamilton-Dutoit (ORCID: https://orcid.org/0000-0003-2158-3885)
- Thomas P. Ahern (ORCID: https://orcid.org/0000-0003-0440-8727)
- Søren Feddersen (ORCID: https://orcid.org/0000-0003-3262-3299)
- Dóra Körmendiné Farkas (ORCID: https://orcid.org/0000-0002-8577-048X)
- Cathrine F. Hjorth (ORCID: https://orcid.org/0000-0003-4378-8531)
Institutions
- University of Vermont (US)
- University of Copenhagen (DK)
- Emory University (US)
- University of Southern Denmark (DK)
- Odense University Hospital (DK)
- Aarhus University Hospital (DK)
- Danish Breast Cancer Cooperative Group (DK)
Publication Details
- Journal
- Breast Cancer Research and Treatment
- Published
- 2024-09-20
- DOI
- https://doi.org/10.1007/s10549-024-07474-9
- Citations
- 1
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- Aarhus Universitet
- Kræftens Bekæmpelse
- Lundbeckfonden
- Novo Nordisk
- Dansk Kræftforsknings Fond
- Novo Nordisk Fonden
- H. Lundbeck A/S
- National Cancer Institute